• Immunome posted an FDA-accepted NDA for varegacestat in adult desmoid tumors; PDUFA target action date April 28, 2027.
• Phase 3 RINGSIDE met its primary endpoint; progression risk cut 84% vs placebo (HR 0.16; p<0.0001).
• Key secondary endpoint also met; objective response rate 56% vs 9% with placebo (p<0.0001).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607080730BIZWIRE_USPR_____20260708_BW283482) on July 08, 2026, and is solely responsible for the information contained therein.